Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis-Reference-Cited by-同舟云学术

Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis

Published:2023-12-23 Issue:2 Volume:76 Page:187-195
ISSN:0163-5581
Container-title:Nutrition and Cancer
language:en
Short-container-title:Nutrition and Cancer

Author:

Wang Haoyu¹²,Yang Ruiyuan¹,Cheng Cheng²,Wang Suyan²,Liu Dan¹,Li Weimin¹²³

Affiliation:

1. Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

2. Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China

3. State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China

Funder

National Natural Science Foundation of China

the Science and Technology Project of Sichuan

project for disciplines of excellence, West China Hospital, Sichuan University

Publisher

Informa UK Limited

Subject

Cancer Research,Nutrition and Dietetics,Oncology,Medicine (miscellaneous)

Link

https://www.tandfonline.com/doi/pdf/10.1080/01635581.2023.2294522

Reference38 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Cancer statistics, 2023

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

5. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Five Prognostic Scores in Patients Receiving Chemoradiation for Primary Glioblastoma Multiforme;In Vivo;2024